Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma

Blood

Volumn 125, Issue 20, 2015, Pages 3100-3104

  Moreau, Philippe ^a   Kolb, Brigitte ^b   Attal, Michel ^c   Caillot, Denis ^d   Benboubker, Lotfi ^e   Tiab, Mourad ^f   Touzeau, Cyrille ^a   Leleu, Xavier ^g   Roussel, Murielle ^c   Chaleteix, Carine ^h   Planche, Lucie ^a   Chiffoleau, Anne ^a   Fortin, June ^a   Avet Loiseau, Hervé ^c   Mary, Jean Yves ⁱ   Hulin, Cyrille ^j   Facon, Thierry ^g  

^a HÔTEL DIEU   (France)

^b REIMS UNIVERSITY HOSPITAL   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d DIJON UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF TOURS   (France)

^f University Hospital   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j UNIVERSITY HOSPITAL OF NANCY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARFILZOMIB; CREATININE; MELPHALAN; PREDNISONE; ANTINEOPLASTIC AGENT; OLIGOPEPTIDE;

AGED; ANEMIA; ARTICLE; ATRIAL FIBRILLATION; CANCER PATIENT; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; INCIDENCE; INFECTION; INVESTIGATIVE PROCEDURES; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; AGE; CANCER STAGING; CLINICAL TRIAL; DRUG MONITORING; MORTALITY; TREATMENT OUTCOME; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG MONITORING; FEMALE; HUMANS; MALE; MELPHALAN; MULTIPLE MYELOMA; NEOPLASM STAGING; OLIGOPEPTIDES; PREDNISONE; TREATMENT OUTCOME;

EID: 84929330382     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-02-626168     Document Type: Article

References (19)

1. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan and prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol. 1998;16(12):3832-3842.
2. Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32(6):587-600.
3. San Miguel JF, Schlag R, Khuageva NK, et al VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-917.
4. Facon T, Mary JY, Hulin C, et al Intergroupe Francophone du Myélome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370(9594):1209-1218.
5. Palumbo A, Hajek R, Delforge M, et al; MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-1769.
6. Benboubker L, Dimopoulos MA, Dispenzieri A, et al FIRST Trial Team. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906-917.
7. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120(14):2817-2825.
8. KYPROLIS. (carfilzomib) prescribing information. South San Francisco, CA: Onyx Pharmaceuticals, Inc.; 2013.
9. Stewart AK, Rajkumar SV, Dimopoulos MA, et al ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142-152.
10. Kortuem KM, Stewart AK. Carfilzomib. Blood. 2013;121(6):893-897.
11. Durie BG, Harousseau JL, Miguel JS, et al International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.
12. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0 (CTCAE), 2013. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc.htm. Accessed April 15, 2013.
13. Mateos MV, Hernández JM, Hernández MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006;108(7):2165-2172.
14. A'Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med. 2001;20(6):859-866.
15. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958;53:457-481.
16. Delforge M, Bladé J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol. 2010;11(11):1086-1095.
17. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431-440.
18. Fayers PM, Palumbo A, Hulin C, et al Nordic Myeloma Study Group; Italian Multiple Myeloma Network; Turkish Myeloma Study Group; Hemato-Oncologie voor Volwassenen Nederland; Intergroupe Francophone du Myélome; European Myeloma Network. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011;118(5):1239-1247.
19. Rajkumar SV, Jacobus S, Callander NS, et al Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29-37.